Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2020 3
2023 3
2024 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Cancer in people with multidrug-resistant HIV.
Clemente T, Pontillo D, Malagnino V, Calza L, Di Biagio A, Cenderello G, Lolatto R, Manzillo E, Moioli MC, De Socio GV, Castagna A, Spagnuolo V; PRESTIGIO Study Group. Clemente T, et al. AIDS. 2024 Oct 1;38(12):1801-1806. doi: 10.1097/QAD.0000000000003952. Epub 2024 Aug 29. AIDS. 2024. PMID: 39206886
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors.
Clemente T, Galli L, Lolatto R, Gagliardini R, Lagi F, Ferrara M, Cattelan AM, Focà E, Di Biagio A, Cervo A, Calza L, Maggiolo F, Marchetti G, Cenderello G, Rusconi S, Zazzi M, Santoro MM, Spagnuolo V, Castagna A; PRESTIGIO Study Group. Clemente T, et al. BMJ Open. 2024 Feb 10;14(2):e080606. doi: 10.1136/bmjopen-2023-080606. BMJ Open. 2024. PMID: 38341206 Free PMC article.
Sexually transmitted infections in people with multidrug-resistant HIV.
Clemente T, Lolatto R, Papaioannu Borjesson R, Fabbiani M, Manzillo E, Fronti E, Di Giambenedetto S, Gagliardini R, Rusconi S, Santoro MM, Castagna A, Spagnuolo V; PRESTIGIO Study Group. Clemente T, et al. AIDS. 2023 Dec 1;37(15):2425-2430. doi: 10.1097/QAD.0000000000003690. Epub 2023 Nov 16. AIDS. 2023. PMID: 37965740
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry.
Armenia D, Spagnuolo V, Bellocchi MC, Galli L, Duca L, Marchegiani G, Clemente T, Carioti L, Lolatto R, Calza L, Celesia BM, Cascio A, Francisci D, Saracino A, Torti C, Zazzi M, Castagna A, Santoro MM; PRESTIGIO Study Group. Armenia D, et al. J Antimicrob Chemother. 2024 Sep 3;79(9):2354-2363. doi: 10.1093/jac/dkae236. J Antimicrob Chemother. 2024. PMID: 39004997
Inflammation burden score in multidrug-resistant HIV-1 infection.
Clemente T, Caccia R, Galli L, Galli A, Poli A, Marchetti GC, Bandera A, Zazzi M, Santoro MM, Cinque P, Castagna A, Spagnuolo V; PRESTIGIO Study Group. Clemente T, et al. J Infect. 2023 May;86(5):453-461. doi: 10.1016/j.jinf.2023.03.011. Epub 2023 Mar 11. J Infect. 2023. PMID: 36913985
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry.
Galli L, Parisi MR, Poli A, Menozzi M, Fiscon M, Garlassi E, Francisci D, Di Biagio A, Sterrantino G, Fornabaio C, Degli Antoni A, Angarano G, Fusco FM, D'Arminio Monforte A, Corbelli GM, Santoro MM, Zazzi M, Castagna A; PRESTIGIO Study Group. Galli L, et al. Open Forum Infect Dis. 2020 Sep 26;7(11):ofaa456. doi: 10.1093/ofid/ofaa456. eCollection 2020 Nov. Open Forum Infect Dis. 2020. PMID: 33241063 Free PMC article.
Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry.
Saladini F, Giammarino F, Maggiolo F, Ferrara M, Cenderello G, Celesia BM, Martellotta F, Spagnuolo V, Corbelli GM, Gianotti N, Santoro MM, Rusconi S, Zazzi M, Castagna A; PRESTIGIO Study Group. Saladini F, et al. Int J Antimicrob Agents. 2023 Mar;61(3):106737. doi: 10.1016/j.ijantimicag.2023.106737. Epub 2023 Jan 25. Int J Antimicrob Agents. 2023. PMID: 36708743
Polypharmacy, anticholinergic burden and drug-drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registry.
Mazzitelli M, Pontillo D, Clemente T, Di Biagio A, Cenderello G, Rusconi S, Menzaghi B, Fornabaio C, Garlassi E, Zazzi M, Castagna A, Cattelan AM; PRESTIGIO Study Group. Mazzitelli M, et al. J Antimicrob Chemother. 2024 Sep 3;79(9):2163-2169. doi: 10.1093/jac/dkae190. J Antimicrob Chemother. 2024. PMID: 39001781
Risk of virological failure after drug burden reduction in people with 4-class drug-resistant HIV on virological suppression: A retrospective cohort analysis of data from the PRESTIGIO Registry.
Clemente T, Diotallevi S, Lolatto R, Gagliardini R, Giacomelli A, Fiscon M, Ferrara M, Cervo A, Calza L, Maggiolo F, Rusconi S, Santoro MM, Castagna A, Spagnuolo V; PRESTIGIO Study Group. Clemente T, et al. Int J Antimicrob Agents. 2024 Jul;64(1):107195. doi: 10.1016/j.ijantimicag.2024.107195. Epub 2024 May 9. Int J Antimicrob Agents. 2024. PMID: 38734216 No abstract available.
13 results